Tetrapyrroles and derivatives
Abcam beta-Amyloid Peptide (42-1) (human), Inactive control, 1MG
MW 4514 Da. beta-Amyloid Peptide (42-1) (human), Inactive control. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam beta-Amyloid Peptide (1-42) (human), 1MG
Beta-amyloid peptide (1-42) (human) is with purity of > 95%. - Reconstitute with PBS at 1 mg/mL
The product is subject to the following: Abcam Restricted Use Statement
Abcam AMD3100 octahydrochloride, C x CR4 antagonist, 50MG
MW 794.5 Da, Purity >99%. Plerixafor (hydrochloride) is a macrocyclic compound that acts as an irreversible antagonist against the binding of CXCR4 with its ligand, SDF-1 (CXCL12). It suppresses infection by HIV with an IC₅₀ value of 1-10 ng/ml with selectivity toward CXCR4-tropic virus. Plerixafor mobilizes hematopoietic stem and progenitor cells for transplant better than G-CSF alone. It also increases T-cell trafficking in the blood and spleen as well as the central nervous system. Plerixafor regulates the growth of primary and metastic breast cancer cells and inhibits dissemination of ovarian carcinoma cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Pancuronium dibromide, Competitive nicotinic acetylcholine receptor antagonist, 50MG
MW 732.7 Da. Competitive nicotinic acetylcholine receptor (nAChR) antagonist. Displaces acetylcholine (ab120469) from nAChRs (IC₅₀ = 5.5 nM). Neuromuscular blocker and muscle relaxant.
The product is subject to the following: Abcam Restricted Use Statement
Abcam QVD-OPh, caspase inhibitor, 5MG
MW 513.5 Da, Purity >95%. QVD-OPh, caspase inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam AR 231453, GPR119 agonist, 25MG
MW 505.5 Da, Purity >99%. Potent, selective G-protein coupled receptor 119 (GPR119) agonist (EC₅₀ = 0.68 nM). Enhances glucose-induced insulin release. Antidiabetic activity. Orally active in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam A 943931 dihydrochloride, H4 receptor antagonist, 10MG
MW 368.3 Da, Purity >99%. Potent and selective H4 receptor antagonist (pKi = 7-8). Shows anti-inflammatory and analgesic effects *in vivo.* Orally active.
The product is subject to the following: Abcam Restricted Use Statement
Abcam C59, Wnt Antagonist, Wnt signaling pathway inhibitor, 1MG
MW 379.5 Da, Purity >97%. Potent Wnt signaling pathway inhibitor. Inhibits porcupine (PORCN) required for Wnt palmitoylation, secretion, and biological activity. Inhibits Wnt-mediated transcription (IC₅₀ = 74 pM) and cell proliferation. Active in vivo..
The product is subject to the following: Abcam Restricted Use Statement
Abcam Clozapine N-o x ide, Metabolite of Clozapine, 5MG
MW 342.8 Da, Purity >99%. Metabolite of atypical antipsychotic Clozapine (ab120019). Active in vitro and in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GM 6001, MMP inhibitor, 5MG
MW 388.5 Da, Purity >98%. Broad spectrum potent MMP inhibitor. Ki values are 0.4 (MMP-1), 0.5 (MMP-2), 27 (MMP-3), 0.1 (MMP-8), 0.2 (MMP-9), 13.4 (MMP-14) and 0.36 (MMP-26) nM. IC₅₀ value for MMP-7 is 3.7 nM. Pharmacologically active in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Nocodazole, Microtubule inhibitor, 5MG
MW 301.32 Da, Purity >98%. Microtubule inhibitor. Rapidly depolymerises microtubules in vivo and inhibits tubulin polymerisation in vitro. Inhibits mitosis. Also reduces stem cell pluripotency factors Oct 4 and Nanog.
The product is subject to the following: Abcam Restricted Use Statement
Abcam CHIR99021, GSK3 inhibitor, 5MG
MW 465.3 Da, Purity >98%. Potent, highly selective aminopyrimidine GSK3 inhibitor (IC₅₀ values are 6.7 and 10 nM at GSK3β and GSK3α, respectively). Exhibits >500-fold selectivity for GSK3 against 20 closely related protein kinases and >800-fold selectivity for 23 additional enzymes and 22 receptors. Promotes self-renewal of mouse and human ESC due to β-catenin and c-Myc protein level stabilization. Commonly used in multiple stages of organoid generation.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SB 216641 hydrochloride, h5-HT1B antagonist, 10MG
MW 523.03 g/mol, Purity >98%. Selective h5-HT₁B receptor antagonist. 25-fold selectivity over h5-HT₁D. Little or no affinity for a range of other receptor subtypes.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SB-277011-A dihydrochloride, D3 antagonist, 25MG
MW 511.5 Da, Purity >98%. Potent, highly selective D3 receptor antagonist (pKi = 7.95 at hD3 receptors). Exhibits over 100-fold selectivity over D2 receptors. Blood-brain barrier (BBB) permeable. Diminishes nicotine, cocaine and alcohol self-administration. Interferes with mechanisms of drug-taking and reinstatement of drug-taking behaviours.
The product is subject to the following: Abcam Restricted Use Statement
Abcam MPEP hydrochloride, mGlu5 antagonist, 10MG
MW 229.7 Da, Purity >99%. Subtype selective and potent non-competitive mGlu₅ antagonist (IC₅₀ = 36 nM). Central effects following systemic administration in vivo.
The product is subject to the following: Abcam Restricted Use Statement